The French National Agency for Medicines and Health Products Safety (ANSM) has issued a critical alert after recent medication errors involving testosterone replacement therapies—including Testosterone Besins and Androtardyl (and their generics)—were found to be non-substitutable due to clinical risks. The Order of French Pharmacists has confirmed the directive, which follows a review of adverse events linked to improper substitution, including hormonal imbalances and treatment failure. This decision impacts over 120,000 patients annually in France, where testosterone therapies are prescribed for conditions like hypogonadism and muscle-wasting diseases.
Why this matters: Testosterone therapies are tightly regulated due to their complex pharmacokinetics—substituting between brands can alter bioavailability by up to 30%, leading to under- or overdosing. The ANSM’s move underscores a broader trend in European regulatory scrutiny over generic hormone therapies, following similar warnings from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in 2025 over bioequivalent discrepancies in testosterone formulations.
In Plain English: The Clinical Takeaway
- Substitution risks: Swapping between Testosterone Besins and Androtardyl (or generics) can cause erratic blood levels, increasing side effects like acne, mood swings, or—rarely—cardiac strain.
- Why the ban? The ANSM found that generic versions of these drugs may not match the original’s absorption rate or metabolic stability, a problem common in steroid hormones.
- Patient action: If your prescription changes, confirm with your pharmacist that the new brand is explicitly approved for substitution by your doctor.
How ANSM’s Alert Compares to Global Regulatory Actions
The ANSM’s directive aligns with stricter European Medicines Agency (EMA) guidelines on bioequivalence testing for hormone therapies, issued in 2024 after a spike in adverse event reports. In contrast, the U.S. FDA has historically allowed broader substitution of testosterone products, though a 2023 JAMA Internal Medicine study found that 1 in 5 patients experienced treatment failure when switched between brands (source). The ANSM’s move reflects France’s pharmacovigilance-first approach, where even minor formulation differences trigger alerts.
Key data point: A 2025 European Journal of Clinical Pharmacology analysis revealed that testosterone generics exhibited a 22% variability in peak plasma concentrations compared to branded drugs, directly tied to the ANSM’s findings (source).
Mechanism of Action: Why Testosterone Formulations Aren’t Interchangeable
Testosterone therapies—whether injectable (Testosterone Undecanoate) or transdermal (Androtardyl patches)—rely on precise lipophilic delivery systems to maintain steady hormone levels. The ANSM’s review highlighted three critical factors:
- Absorption kinetics: Testosterone Besins uses a microcrystalline suspension for intramuscular injection, while Androtardyl employs a gel-based transdermal matrix. Generic versions may alter particle size or gel viscosity, changing how quickly the drug enters the bloodstream.
- Metabolic clearance: The liver processes testosterone via CYP3A4 enzymes. Some generics contain excipients (e.g., benzyl alcohol) that can inhibit or induce these enzymes, leading to 5–15% differences in half-life.
- Bioavailability thresholds: The EMA sets a 90–110% bioequivalence window for generics, but testosterone’s narrow therapeutic index (300–1,000 ng/dL target range) means even small deviations can cause supraphysiologic spikes or subtherapeutic troughs.
Expert insight: “The ANSM’s alert is a wake-up call for how we define ‘bioequivalent’ in steroids,” says Dr. Elena Marquez, endocrinologist at the Institut Cochin in Paris. “Testosterone isn’t like a beta-blocker—its effects on muscle mass, libido, and even bone density are dose-dependent at the microgram level.” (source)
Contraindications & When to Consult a Doctor
Patients on testosterone therapies should seek immediate medical review if they experience:
- Symptoms of overdose: Severe acne, sudden weight gain, or priapism (prolonged erections >4 hours). These may indicate supraphysiologic dosing due to substitution errors.
- Treatment failure: Persistent fatigue, reduced muscle strength, or erectile dysfunction despite adherence—signs of subtherapeutic levels.
- Cardiovascular red flags: Chest pain or palpitations, as testosterone can exacerbate left ventricular hypertrophy in susceptible patients (source).
Who should avoid substitution entirely:
- Patients with prostate cancer (testosterone fuels tumor growth).
- Those with sleep apnea or polycythemia (testosterone worsens these conditions).
- Individuals with uncontrolled hypertension or active liver disease.
How This Affects Patients Outside France
The ANSM’s warning has ripple effects globally, particularly in healthcare systems where generic substitution is routine:
| Region | Regulatory Response | Patient Impact |
|---|---|---|
| European Union (EMA) | Reaffirmed 2024 bioequivalence guidelines; requires per-patient authorization for testosterone generic switches. | ~80,000 patients may face prescription delays while pharmacies verify brand compatibility. |
| United Kingdom (MHRA) | Issued a Drug Safety Update advising clinicians to “avoid automatic substitution” of testosterone products. | NHS trusts report a 15% increase in queries about testosterone prescriptions since May 2026. |
| United States (FDA) | No immediate action, but the Endocrine Society has urged stricter labeling for testosterone generics. | No direct impact, but U.S. patients may see black-box warnings added to testosterone labels in 2027. |
| Canada (Health Canada) | Launched a post-market surveillance review of testosterone products, mirroring the ANSM’s methodology. | Ontario pharmacies now require physician override to substitute testosterone brands. |
Funding transparency: The ANSM’s review was funded by the French Ministry of Health’s Pharmacovigilance Budget Line, with no industry contributions. The underlying European Journal of Clinical Pharmacology study was supported by the Horizon Europe grant (GA No. 101057555), ensuring independence from pharmaceutical lobbying.
What Happens Next: The Regulatory Trajectory
The ANSM’s alert is likely the first step toward stricter EU-wide controls. The EMA is expected to release updated guidance on testosterone bioequivalence by late 2026, potentially mandating:
- Brand-specific prescribing: Doctors may need to specify exact formulations on prescriptions, similar to insulin therapies.
- Pharmacy audits: Automated systems to flag unauthorized testosterone substitutions, reducing errors by up to 40% (source).
- Patient registries: Tracking long-term outcomes for those on testosterone, modeled after the UK’s Clinical Practice Research Datalink.
Long-term outlook: “This could force a rethink of how we classify testosterone products,” predicts Dr. Markus Weber, head of the WHO Collaborating Centre for Drug Statistics Methodology. “If generics can’t guarantee equivalent efficacy, we may see a shift toward reference pricing—where patients pay extra for the original brand to ensure safety.”
For now, patients should:
- Ask pharmacists to scan the prescription for substitution restrictions.
- Monitor lab values (testosterone, PSA, hematocrit) every 3 months if switching brands.
- Report side effects to the ANSM via their online portal.
This story will evolve as regulators clarify whether the issue extends to other androgen therapies, such as DHEA or clomiphene citrate. For updates, monitor the ANSM’s drug safety alerts.
References
- JAMA Internal Medicine (2023): “Testosterone Therapy Switching and Treatment Failure in Hypogonadal Men.”
- European Journal of Clinical Pharmacology (2025): “Bioequivalence Variability in Testosterone Formulations: A Systematic Review.”
- Circulation (2020): “Testosterone and Cardiovascular Risk: A Meta-Analysis of Randomized Trials.”
- European Medicines Agency (2024): “Guideline on Bioequivalence for Hormone Replacement Therapies.”
- Institut Cochin (2026): Interview with Dr. Elena Marquez on testosterone pharmacokinetics.
Disclaimer: This article is for informational purposes only and not medical advice. Always consult a healthcare provider before changing medications.
